Cargando…
Surveillance of women at high risk for hereditary ovarian cancer is inefficient
To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylact...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361371/ https://www.ncbi.nlm.nih.gov/pubmed/16495917 http://dx.doi.org/10.1038/sj.bjc.6603015 |
_version_ | 1782153200133996544 |
---|---|
author | Oei, A L Massuger, L F Bulten, J Ligtenberg, M J Hoogerbrugge, N de Hullu, J A |
author_facet | Oei, A L Massuger, L F Bulten, J Ligtenberg, M J Hoogerbrugge, N de Hullu, J A |
author_sort | Oei, A L |
collection | PubMed |
description | To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylactic bilateral salpingo-oophorectomy (BSO). Study population consisted of 512 high-risk women (median follow-up 2.07 years, range 0–9.4 years): 265 women (52%) had a BRCA mutation. Persisting abnormalities indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found. The effectiveness of screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing this to the identified number of ovarian cancers. The number of ovarian cancer patients found at surveillance was in accordance with the predicted number of ovarian cancers. A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb was found. In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient. For prevention of advanced stage ovarian cancer, prophylactic BSO from age 35–40 years is a more efficient alternative. |
format | Text |
id | pubmed-2361371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23613712009-09-10 Surveillance of women at high risk for hereditary ovarian cancer is inefficient Oei, A L Massuger, L F Bulten, J Ligtenberg, M J Hoogerbrugge, N de Hullu, J A Br J Cancer Clinical Study To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylactic bilateral salpingo-oophorectomy (BSO). Study population consisted of 512 high-risk women (median follow-up 2.07 years, range 0–9.4 years): 265 women (52%) had a BRCA mutation. Persisting abnormalities indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found. The effectiveness of screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing this to the identified number of ovarian cancers. The number of ovarian cancer patients found at surveillance was in accordance with the predicted number of ovarian cancers. A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb was found. In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient. For prevention of advanced stage ovarian cancer, prophylactic BSO from age 35–40 years is a more efficient alternative. Nature Publishing Group 2006-03-27 2006-02-21 /pmc/articles/PMC2361371/ /pubmed/16495917 http://dx.doi.org/10.1038/sj.bjc.6603015 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Oei, A L Massuger, L F Bulten, J Ligtenberg, M J Hoogerbrugge, N de Hullu, J A Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title | Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title_full | Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title_fullStr | Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title_full_unstemmed | Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title_short | Surveillance of women at high risk for hereditary ovarian cancer is inefficient |
title_sort | surveillance of women at high risk for hereditary ovarian cancer is inefficient |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361371/ https://www.ncbi.nlm.nih.gov/pubmed/16495917 http://dx.doi.org/10.1038/sj.bjc.6603015 |
work_keys_str_mv | AT oeial surveillanceofwomenathighriskforhereditaryovariancancerisinefficient AT massugerlf surveillanceofwomenathighriskforhereditaryovariancancerisinefficient AT bultenj surveillanceofwomenathighriskforhereditaryovariancancerisinefficient AT ligtenbergmj surveillanceofwomenathighriskforhereditaryovariancancerisinefficient AT hoogerbruggen surveillanceofwomenathighriskforhereditaryovariancancerisinefficient AT dehulluja surveillanceofwomenathighriskforhereditaryovariancancerisinefficient |